Chronic Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Chronic Pain - Pipeline Review, H2 2016

Chronic Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Chronic Pain - Pipeline Review, H2 2016
Published Sep 14, 2016
335 pages — Published Sep 14, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Chronic Pain - Pipeline Review, H2 2016, provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Pain
- The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects
- The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Pain


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in

  
Source:
Document ID
GMDHC8545IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents218
  List of Tables172
  List of Figures191
Introduction201
  Global Markets Direct Report Coverage201
Chronic Pain Overview211
Therapeutics Development222
  Pipeline Products for Chronic Pain Overview221
  Pipeline Products for Chronic Pain Comparative Analysis231
Chronic Pain Therapeutics under Development by Companies247
Chronic Pain Therapeutics under Investigation by Universities/Institutes311
Chronic Pain Pipeline Products Glance324
  Late Stage Products321
  Clinical Stage Products331
  Early Stage Products341
  Unknown Stage Products351
Chronic Pain Products under Development by Companies368
Chronic Pain Products under Investigation by Universities/Institutes441
Chronic Pain Companies Involved in Therapeutics Development4566
  AbbVie Inc451
  Acadia Pharmaceuticals Inc.461
  Adynxx, Inc.471
  Allergan Plc481
  Amorsa Therapeutics Inc.491
  arGEN-X BV501
  Asana BioSciences, LLC511
  AskAt Inc.521
  Astraea Therapeutics, LLC531
  Axsome Therapeutics, Inc.541
  BioDelivery Sciences International, Inc.551
  Biogen Inc561
  Bionomics Limited571
  Camurus AB581
  Cara Therapeutics, Inc.591
  Centrexion Therapeutics Corp601
  ChironWells GmbH611
  Collegium Pharmaceutical, Inc.621
  Crinetics Pharmaceuticals, Inc.631
  Cyclenium Pharma, Inc.641
  Cytogel Pharma, LLC651
  Daewoong Pharmaceutical Co., Ltd.661
  Daiichi Sankyo Company, Limited671
  Dompe Farmaceutici S.p.A.681
  Echo Pharmaceuticals B.V.691
  Egalet Corporation701
  Eli Lilly and Company711
  Elite Pharmaceuticals, Inc.721
  Glenmark Pharmaceuticals Ltd.731
  Grunenthal GmbH741
  Heron Therapeutics, Inc.751
  INSYS Therapeutics, Inc.761
  Johnson &Johnson771
  Kareus Therapeutics, SA781
  KPI Therapeutics, Inc.791
  Kymab Limited801
  Laboratorios Del Dr. Esteve S.A.811
  Lohocla Research Corporation821
  Lpath, Inc.831
  MD Biosciences GmbH841
  Merck &Co., Inc.851
  Moberg Pharma AB861
  Mundipharma International Ltd871
  Nanomerics Ltd881
  Nektar Therapeutics891
  Neura Therapeutik, LLC901
  Orion Oyj911
  Pacira Pharmaceuticals, Inc.921
  Pain Therapeutics, Inc.931
  PeriphaGen, Inc.941
  Pfizer Inc.951
  Phosphagenics Limited961
  Prismic Pharmaceuticals, Inc.971
  Purdue Pharma LP981
  Relmada Therapeutics, Inc.991
  Ribomic Inc.1001
  Sea4Us1011
  Shulov Innovative Science Ltd.1021
  Synactix Pharmaceuticals, Inc.1031
  Syntrix Biosystems, Inc.1041
  Teva Pharmaceutical Industries Ltd.1051
  Therapix Biosciences Ltd.1061
  Trevena, Inc.1071
  Voyager Therapeutics, Inc.1081
  Yooyoung Pharmaceutical Co., Ltd.1091
  Zynerba Pharmaceuticals, Inc.1101
Chronic Pain Therapeutics Assessment11120
  Assessment by Monotherapy Products1111
  Assessment by Combination Products1121
  Assessment by Target1137
  Assessment by Mechanism of Action1207
  Assessment by Route of Administration1272
  Assessment by Molecule Type1292
Drug Profiles131183
  (celecoxib + tramadol hydrochloride) Drug Profile1312
  (hydrocodone bitartrate + palmidrol) Drug Profile1331
  (morphine sulfate + palmidrol) Drug Profile1341
  (naltrexone hydrochloride + oxycodone hydrochloride) SR Drug Profile1351
  (oxycodone hydrochloride + palmidrol) Drug Profile1361
  (palmidrol + pregabalin) Drug Profile1371
  A-200 Drug Profile1381
  AGN-XX Drug Profile1391
  AGN-YY Drug Profile1401
  AMS-520 Drug Profile1411
  ASN-008 Drug Profile1421
  AVLX-144 Drug Profile1431
  AXS-06 Drug Profile1441
  AYX-1 Drug Profile1452
  AYX-2 Drug Profile1471
  BBI-11008 Drug Profile1481
  bupivacaine Drug Profile1492
  bupivacaine hydrochloride Drug Profile1512
  buprenorphine hydrochloride Drug Profile1532
  buprenorphine hydrochloride depot Drug Profile1551
  buprenorphine hydrochloride ER Drug Profile1562
  buprenorphine hydrochloride long acting Drug Profile1581
  cebranopadol Drug Profile1593
  cetirizine hydrochloride + cromolyn sodium Drug Profile1621
  cetuximab Drug Profile1636
  CNTX-0290 Drug Profile1691
  CNV-3000164 Drug Profile1701
  CNV-3000223 Drug Profile1711
  CR-4056 Drug Profile1721
  CR-701 Drug Profile1731
  CRB-0089 Drug Profile1741
  Cyt-1010 Drug Profile1752
  dexmedetomidine hydrochloride Drug Profile1772
  DF-2593A Drug Profile1791
  difelikefalin Drug Profile1807
  dronabinol Drug Profile1872
  DS-1971 Drug Profile1891
  DWJ-208 Drug Profile1901
  ECP-1014 Drug Profile1911
  Egalet-003 Drug Profile1921
  fluticasone propionate Drug Profile1931
  FY-101C Drug Profile1941
  FY-103B Drug Profile1951
  GBR-900 Drug Profile1961
  Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain Drug Profile1971
  grapiprant Drug Profile1982
  HPI-201 Drug Profile2001
  HS-731 Drug Profile2011
  hydrocodone bitartrate ER Drug Profile2023
  hydrocodone bitartrate ER Drug Profile2051
  hydrocodone bitartrate ER Drug Profile2061
  hydromorphone hydrochloride Drug Profile2071
  Kindolor Drug Profile2081
  KY-1017 Drug Profile2091
  L-779976 Drug Profile2101
  lacosamide Drug Profile2111
  LEVI-04 Drug Profile2121
  levorphanol tartrate ER Drug Profile2132
  Lpathomab Drug Profile2153
  MD-354 Drug Profile2181
  Monoclonal Antibodies for Chronic Pain Drug Profile2191
  Monoclonal Antibodies to Block Nav1.7 for Chronic Pain Drug Profile2201
  morphine sulfate ER Drug Profile2214
  MR-309 Drug Profile2252
  NET-END Drug Profile2271
  NKTR-181 Drug Profile2283
  NL-001 Drug Profile2311
  NL-002 Drug Profile2321
  NM-0127 Drug Profile2331
  Omnitram Drug Profile2341
  onabotulinumtoxin A Drug Profile2355
  OSX-300 Drug Profile2401
  OSX-300 Backups Drug Profile2411
  oxycodone hydrochloride ER Drug Profile2423
  oxycodone hydrochloride ER Drug Profile2451
  oxycodone hydrochloride ER Drug Profile2462
  oxymorphone hydrochloride Drug Profile2481
  oxymorphone hydrochloride ER Drug Profile2491
  PAC-CP Drug Profile2501
  palmidrol Drug Profile2511
  Peptide to Block Cav2.2 for CNS Disorders Drug Profile2521
  Peptides to Inhibit Ion Channel for Chronic Pain Drug Profile2531
  Peptides to Target TRPV1 for Pain and Itch Drug Profile2541
  PN-6047 Drug Profile2551
  PRC-062 Drug Profile2561
  Prostatic Acid Phosphatase Drug Profile2571
  PspTx-3 Drug Profile2581
  raxatrigine hydrochloride Drug Profile2593
  RBM-005 Drug Profile2621
  REL-1017 Drug Profile2633
  SAFit2 Drug Profile2661
  Small Molecule for Chronic Pain Drug Profile2671
  Small Molecule for Chronic Pain Drug Profile2681
  Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain Drug Profile2691
  Small Molecule to Antagonize GPR-84 for Chronic Pain Drug Profile2701
  Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders Drug Profile2712
  Small Molecule to Block Nav1.9 Channel for Pain Drug Profile2731
  Small Molecule to Inhibit ASK-1 for Chronic Pain Drug Profile2741
  Small Molecule to Inhibit mPGES-1 for Chronic Pain Drug Profile2751
  Small Molecules for Chronic Wound Pain Drug Profile2761
  Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder Drug Profile2771
  Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain Drug Profile2781
  Small Molecules to Agonize CB2 for Chronic Pain and Migraine Drug Profile2791
  Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain Drug Profile2801
  Small Molecules to Agonize NOP for Pain and Alcohol Addiction Drug Profile2811
  Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain Drug Profile2821
  Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain Drug Profile2831
  Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System Drug Profile2841
  Small Molecules to Block Cav2.2 Channel for Chronic Pain Drug Profile2851
  Small Molecules to Block Cav2.2 Channel for Chronic Pain Drug Profile2861
  Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain Drug Profile2871
  Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain Drug Profile2881
  Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System Drug Profile2891
  Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain Drug Profile2901
  Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain Drug Profile2911
  Small Molecules to Inhibit DAAO for Chronic Pain Drug Profile2921
  Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain Drug Profile2931
  Small Molecules to Target Opioid Receptors for Chronic Pain Drug Profile2941
  SYN-003 Drug Profile2951
  Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain Drug Profile2961
  tanezumab Drug Profile2973
  tapentadol hydrochloride IR Drug Profile3002
  TRV-734 Drug Profile3022
  U-2902 Drug Profile3042
  UMB-425 Drug Profile3061
  Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain Drug Profile3071
  VM-902A Drug Profile3081
  VYNAV-01 Drug Profile3091
  XT-101 Drug Profile3101
  YYC-301 Drug Profile3111
  ZEP-3 Drug Profile3121
  ZYN-001 Drug Profile3131
Chronic Pain Dormant Projects3149
Chronic Pain Discontinued Products3233
Chronic Pain Product Development Milestones3268
  Featured News &Press Releases3261
    Aug 25, 2016: Egalet Announces Scientific Presentation on ARYMO ER (morphine sulfate) at PAINWeek 2016 Meeting3261
    Jul 13, 2016: Cara Therapeutics Data to be Presented at the British Association for Psychopharmacology 2016 Summer Meeting3271
    Jul 01, 2016: Pain Therapeutics Announces Advisory Committee Meeting for REMOXY Is Not Needed3271
    Jun 22, 2016: Collegium Announces Positive Topline Results for Hydrocodone DETERx Clinical Study3271
    Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings3281
    Jun 07, 2016: Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELA ER (hydrocodone bitartrate) Extended-Release Tablets CII Formulated with Proprietary Abuse Deterrence Technology3281
    Jun 03, 2016: New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA (Buprenorphine) Buccal Film For Chronic Pain3291
    May 19, 2016: Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY3301
    May 11, 2016: Pain Therapeutics To Present New Remoxy Data At American Pain Society Meeting3311
    Apr 29, 2016: Voyager Therapeutics Announces Update on VY-NAV01 at R&D Day3311
    Apr 12, 2016: DURECT Announces FDA Acceptance of REMOXY NDA, PDUFA Date of September 25, 20163321
    Mar 29, 2016: DURECT Announces Resubmission of REMOXY New Drug Application to the U.S. Food and Drug Administration3321
    Mar 08, 2016: Relmada Therapeutics to Present at the 28th Annual ROTH Conference3321
    Mar 04, 2016: BioDelivery Sciences to provide an update on BELBUCA (buprenorphine) at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference3331
Appendix3342
  Methodology3341
  Coverage3341
  Secondary Research3341
  Primary Research3341
  Expert Panel Validation3341
  Contact Us3341

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Chronic Pain - Pipeline Review, H2 2016" Sep 14, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chronic-Pain-Pipeline-Review-H2-2016-2088-16551>
  
APA:
Global Markets Direct - Market Research. (2016). Chronic Pain - Pipeline Review, H2 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chronic-Pain-Pipeline-Review-H2-2016-2088-16551>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.